Research Article
Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors
Table 1
Baseline characteristics of the patients.
| Variable | | Number of patients/Value | Percentage (%) |
| Gender | Male | 80 | 77.67 | Female | 23 | 22.33 | Age | Median | 61 | — | Scope | 24–77 | ECOG PS | 0 | 17 | 16.50 | 1 | 86 | 83.50 | Body mass index | Mean value | 23.4 | — | Scope | 15.8–31.2 | Tumor type | Lung cancer | 51 | 49.51 | Melanoma | 15 | 14.56 | Esophageal cancer | 11 | 10.68 | Liver cancer | 9 | 8.74 | Urothelial carcinoma | 7 | 6.80 | Gastric cancer | 5 | 4.85 | Other types of tumors | 5 | 4.85 | Distant metastasis | No distant organ metastasis | 65 | 63.10 | One or more distant metastatic cancers | 38 | 36.90 | Prior therapy | Chemotherapy | 67 | 65.05 | Radiotherapy | 22 | 21.36 | Targeted therapy | 8 | 7.77 | Immunotherapy | 3 | 2.91 | Other therapies (interferon therapy and interventional/radiofrequency ablation therapy) | 9 | 8.74 | Treatment lines | First-line | 26 | 25.24 | Nonfirst-line | 77 | 74.76 | Treatment regimen | Anti-PD-1 | 80 | 77.67 | Anti-PD-L1 | 13 | 12.62 | Anti-PD-1 + anti-CTLA-4 | 10 | 9.71 |
|
|
—Represents no usability data.
|